Sugi Predict

Sugi Predict / Targets / GBA2

GBA2

Beta-glucosidase · Q9HCG7 · GBA2 on Sugi Atlas →

21,133 patent compounds predicted against GBA2, 11,605 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL466539 SCHEMBL466539 0.55 19/20
Miglustat Miglustat (SCHEMBL246893) 1.00 18/20
Miglustat Miglustat (SCHEMBL719055) 1.00 18/20
SCHEMBL941202 SCHEMBL941202 0.57 18/20
SCHEMBL1072083 SCHEMBL1072083 0.41 14/20
Miglitol Miglitol (SCHEMBL22593) 0.68 13/20
Miglitol Miglitol (SCHEMBL682218) 0.68 13/20
SCHEMBL1009907 SCHEMBL1009907 0.54 13/20
SCHEMBL455365 SCHEMBL455365 0.47 13/20
SCHEMBL456428 SCHEMBL456428 0.44 13/20
SCHEMBL102757 SCHEMBL102757 0.39 13/20
SCHEMBL625268 SCHEMBL625268 0.39 13/20
Emiglitate Emiglitate (SCHEMBL26909) 0.48 11/20
SCHEMBL1115457 SCHEMBL1115457 0.44 10/20
SCHEMBL1072080 SCHEMBL1072080 0.39 10/20
SCHEMBL942535 SCHEMBL942535 0.53 9/20
SCHEMBL469613 SCHEMBL469613 0.38 9/20
SCHEMBL366469 SCHEMBL366469 0.53 8/20
SCHEMBL466824 SCHEMBL466824 0.53 8/20
SCHEMBL1629697 SCHEMBL1629697 0.41 8/20

Clinical trials — most relevant to GBA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
High-Dose Ambroxol in GBA1-Related Parkinson PHASE1/PHASE2UNKNOWN
Ambroxol as a Treatment for Parkinson's Disease Dementia PHASE2UNKNOWN
Ambroxol as a Disease-modifying Treatment in GBA-PD PHASE2COMPLETED
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease PHASE2UNKNOWN
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD PHASE2ACTIVE_NOT_RECRUITING
Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease PHASE2WITHDRAWN
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia PHASE1/PHASE2NOT_YET_RECRUITING
An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease EARLY_PHASE1RECRUITING
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Biomarkers Related to Bone in Pediatric Gaucher Disease nanUNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Biomarker for Patients With Fabry Disease (BioFabry) nanWITHDRAWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
Biomarker for Gaucher Disease: BioGaucher (BioGaucher) nanWITHDRAWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
Biomarker Analysis for GBA Associated Parkinson's Disease nanUNKNOWN
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Prodromal Parkinsonian Features in GBA1 Mutation Carriers nanRECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Italian Anderson Fabry Disease Cardiovascular Registry nanRECRUITING
Assessment of Neurological Manifestations in Gaucher Disease Patients nanUNKNOWN
Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies nanCOMPLETED
Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations nanCOMPLETED
A Natural History of Late Onset Tay-Sachs Disease nanCOMPLETED
Miglustat on Gaucher Disease Type IIIB nanUNKNOWN
Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C nanUNKNOWN
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells in Gaucher Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GBA2 binder may also engage these)

ProteinNameSimilarity
Q69ZF3 — 1.000 Q69ZF3 →
Q5M868 — 0.999 Q5M868 →
F1NZI4 — 0.983 F1NZI4 →
Q8BP56 — 0.970 Q8BP56 →
ABHD16A Phosphatidylserine lipase ABHD16A 0.969 landscape →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.967 landscape →
P52850 — 0.966 P52850 →
Q32M88 — 0.966 Q32M88 →
Q148G5 — 0.966 Q148G5 →
Q1JPD2 — 0.966 Q1JPD2 →
Q14CH1 — 0.966 Q14CH1 →
Q5NVK5 — 0.965 Q5NVK5 →
POLG DNA polymerase subunit gamma-1 0.964 landscape →
Q4R8P0 — 0.964 Q4R8P0 →
A6NFQ2 — 0.964 A6NFQ2 →
Q91YR5 — 0.963 Q91YR5 →
Q6Q0N3 — 0.963 Q6Q0N3 →
Q9WU79 — 0.963 Q9WU79 →
TRPM4 Transient receptor potential cation channel subfamily M member 4 0.962 landscape →
Q4V7A9 — 0.962 Q4V7A9 →
O97583 — 0.962 O97583 →
Q61161 — 0.962 Q61161 →
Q810A5 — 0.962 Q810A5 →
Q68EN5 — 0.962 Q68EN5 →
Q7TN37 — 0.961 Q7TN37 →
Q9QYV8 — 0.961 Q9QYV8 →
Q9D2Q2 — 0.960 Q9D2Q2 →
Q8VCT3 — 0.960 Q8VCT3 →
Q5R6S0 — 0.960 Q5R6S0 →
Q04519 — 0.960 Q04519 →